U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07312110) titled 'D-SPARK: A Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression' on Nov. 21, 2025.
Brief Summary: This clinical study, designed as a randomized, double-blind, placebo-controlled trial, aims to investigate if modulation of the N-methyl-D-aspartate receptor (NMDAR) via its co-agonist D-serine has therapeutic benefits in Parkinson's disease (PD). All patients will receive both placebo and D-serine over different time periods during the study.
Preclinical studies have shown that blocking glycine transporters, which elevates endogenous glycine levels, can restore NMDAR function and improve motor deficits in PD models....